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OBJECTIVE — To evaluate factors associated with successful use of continuous glucose
monitoring (CGM) among participants with intensively treated type 1 diabetes in the Juvenile
Diabetes Research Foundation Continuous Glucose Monitoring Randomized Clinical Trial.
RESEARCH DESIGN AND METHODS — The 232 participants randomly assigned to
the CGM group (165 with baseline A1C 7.0% and 67 with A1C 7.0%) were asked to use
CGM on a daily basis. The associations of baseline factors and early CGM use with CGM use 6
days/week in the 6th month and with change in A1C from baseline to 6 months were evaluated
in regression models.
RESULTS — The only baseline factors found to be associated with greater CGM use in month
6wereage25years(P0.001)andmorefrequentself-reportedprestudybloodglucosemeter
measurements per day (P  0.001). CGM use and the percentage of CGM glucose values
between 71 and 180 mg/dl during the 1st month were predictive of CGM use in month 6 (P 
0.001 and P  0.002, respectively). More frequent CGM use was associated with a greater
reduction in A1C from baseline to 6 months (P  0.001), a ﬁnding present in all age-groups.
CONCLUSIONS — After 6 months, near-daily CGM use is more frequent in intensively
treated adults with type 1 diabetes than in children and adolescents, although in all age-groups
near-daily CGM use is associated with a similar reduction in A1C. Frequency of blood glucose
metermonitoringandinitialCGMusemayhelppredictthelikelihoodoflong-termCGMbeneﬁt
in intensively treated patients with type 1 diabetes of all ages.
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D
espite recent advances in insulin
delivery and home blood glucose
monitoring, many individuals with
type 1 diabetes fail to achieve recom-
mended A1C target levels (1,2). Further,
hypoglycemia is a problem for many pa-
tients with type 1 diabetes (3) and can be
a signiﬁcant deterrent to achieving and
maintaining tight glycemic control (4,5).
Thus, the introduction of real-time con-
tinuous glucose monitoring (CGM) sys-
tems was received with great interest
because these devices may have the po-
tential to increase the proportion of pa-
tientswhoareabletomaintaintargetA1C
valueswhilesimultaneouslylimitingtheir
risk of severe hypoglycemia. The ﬁrst real-
time CGM device, the GlucoWatch Bio-
grapher (6), was difﬁcult to use, in large
partbecauseofskinreactionandfrequent
skipping of glucose measurements that
prevented patients from using it as a tool
for day-to-day diabetes management.
More recently, several new real-time
CGM systems have been introduced that
have improved accuracy, functionality,
and user tolerance.
In a multicenter randomized con-
trolled trial, our Juvenile Diabetes Re-
search Foundation (JDRF) Continuous
Glucose Monitoring Study Group evalu-
ated the effectiveness of CGM compared
with standard blood glucose monitoring
in 451 adults and children 8 years old
with type 1 diabetes, 322 of whom had
baseline A1C 7.0% and 129 of whom
had baseline A1C 7.0% (7). Among
subjects with baseline A1C level 7.0%,
we found that CGM substantially im-
provedA1Clevelsduring6monthsoffol-
low-up without increasing the frequency
of hypoglycemia in adults 25 years of
age.However,theefﬁcacyofthisdeviceas
a tool to help participants 25 years of
age lower their A1C levels was much
more limited (8). Among the subjects
with baseline A1C 7.0%, we found that
the CGM group had a reduction in hypo-
glycemia on most measures compared
with the control group and was able to
maintain mean A1C levels at 6.4%,
whereas A1C increased in the control
group(9).Thepresentanalyseswerecon-
ducted to determine which demographic,
clinical, and psychosocial factors were as-
sociated with successful CGM use and
A1C improvement in the 232 CGM-
group subjects.
RESEARCH DESIGN AND
METHODS— The randomized trial
protocol has been described in detail (7–
9). This report includes the 6-month fol-
low-up of the 232 subjects in the CGM
group, including both the 7.0% (n 
165) and 7.0% (n  67) A1C cohorts.
Major eligibility criteria for the trial in-
cludedage8years,type1diabetesforat
least 1 year, use of either an insulin pump
oratleastthreeinsulininjectionsperday,
and A1C level 10.0%. Randomization
was stratiﬁed in three age-groups: 25,
15–24, and 8–14 years old. Subjects in
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CGM device on a daily basis and were
provided with written instructions on
how to use the CGM data to make real-
time insulin dose adjustments and on us-
ing computer software (for those with a
homecomputer)toretrospectivelyreview
the glucose data to alter future insulin
dosing (7,10). Glucose data from the
CGM devices were downloaded at each
visit. A central laboratory-measured A1C
level was obtained at baseline, 3 months,
and 6 months at the University of Minne-
sota using the Tosoh A1C 2.2 Plus Glyco-
hemoglobin Analyzer method (11).
Statistical methods
The amount of CGM use was determined
from the information downloaded from
theCGMdevices.CGMwasconsideredto
be used on a day when there was at least
one sensor glucose value; on 85% of days
withatleastoneglucosevalue,therewere
atleast12hofglucosevalues.Factorsthat
were evaluated for association with CGM
use included baseline demographic and
clinical characteristics as well as psycho-
social factors that included total and sub-
scale scores from the Hypoglycemia Fear
Survey (12), Blood Glucose Monitoring
System Rating Questionnaire (developed
for the study), and Problem Area in Dia-
betes Questionnaire (13,14).
Logistic regression analyses were
used to evaluate the association between
baseline demographic and clinical factors
(listed in Table 1) and successful CGM
use, which was deﬁned as average use of
6.0 days/week during the 6th month of
the trial. Baseline demographic and clini-
cal factors were included in an initial
model and then a backward elimination
procedure was used to remove variables
with P  0.05. A forward selection pro-
cess resulted in a similar model. Addi-
tional models evaluated the predictive
valueofCGMusageduringthe1stmonth
as well as CGM glucose indexes of the
percentage of glucose values between 71
and 180, 70, and 180 mg/dl. The van
der Waerden normal scores of the CGM
usage were used in the models as a result
of the skewed distribution of the data. A
general linear model was used to evaluate
demographic and clinical factors associ-
ated with a change in A1C from baseline
to 6 months among subjects with a base-
line A1C level 7.0%. The association
between sensor use over the 6 months of
the trial and change in A1C from baseline
to 6 months also was evaluated with a
general linear model.
Analyses were performed using SAS
(version 9.1; SAS Institute, Cary, NC). All
P values are two-sided. For models 1 and
2inTable1,missingvalueswereimputed
for covariates, and an indicator for miss-
ing values was added to the regression.
One subject was missing sensor data for
the 1st month because of a defective de-
vice from which information could not
be downloaded and is excluded from Ta-
ble 2.
RESULTS— The 232 subjects in the
trial’s CGM group ranged in age from 8 to
73 years, with 86 (37%) aged 25 years
old, 72 (31%) aged 15–24 years old, and
74 (32%) aged 8–14 years old. Mean
baseline A1C level was 7.4%  0.9%,
with 165 (71%) at 7.0% and 67 (29%)
at 7.0%. Insulin pump therapy was the
treatment modality in 190 (82%) sub-
jects, with the others being treated with
multiple daily injections. The mean num-
ber of self-reported home blood glucose
measurements per day was 6.6  2.3
measurements. Additional baseline char-
acteristics have been previously reported
(8,9).
Factors associated with CGM use
CGM use averaged 6.0 days/week dur-
ing month 6 of the study in 123 (53%) of
the 232 subjects. As shown in Table 1,
CGM use averaging 6.0 days/week in
month 6 was associated with age (highest
in adults, P  0.001 in a multivariate
model) and frequency of self-reported
prestudy daily blood glucose meter mea-
surements (P  0.001). For the latter fac-
tor, the association was consistent across
the three age-groups (Supplementary Ta-
ble 1, available in an online appendix at
http://care.diabetesjournals.org/cgi/
content/full/dc09-0889/DC1,
shows the factors in Table 1 in three age-
groups). There was a trend toward base-
line A1C 7.0% being associated with
greater CGM use in an unadjusted model
but not after adjustment for age and fre-
quency of prestudy daily blood glucose
meter measurements. Other variables as-
sociated with CGM use that were con-
founded by age included race/ethnicity,
duration of diabetes, educational level,
and household income. When we exam-
ined the psychosocial measures, we
found that none of the total or subscale
scores were signiﬁcantly associated
with CGM use.
AsshowninTable2,CGMuseduring
the1stmonthofthetrialwaspredictiveof
use in month 6 (P  0.001, after adjust-
ment for age and baseline frequency of
daily blood glucose measurements). Sub-
jectswhousedtheCGMdeviceonatleast
27 of the 28 days during the 1st month
weremorethanthreetimesmorelikelyto
be using the device 6 days/week in
month 6 than were subjects who used the
device fewer than 21 of the ﬁrst 28 days.
Resultsaccordingtoage-groupareshown
in supplementary Table 2 (available in an
online appendix).
In addition to the amount of use dur-
ing the 1st month, a higher percentage of
CGM glucose values between 71 and 180
mg/dl during month 1 was predictive of
greater CGM use during month 6 (P 
0.002 adjusted for age, baseline fre-
quency of daily blood glucose meter mea-
surements,andsensoruseduringtheﬁrst
4 weeks) (Table 2). In similar models, a
lower percentage of glucose values 180
in the 1st month was associated with
greater use in month 6 (P  0.006), but a
lower percentage of glucose values 70
mg/dlwasnot(P0.91).Thepercentage
of glucose values 180 mg/dl was associ-
ated with baseline A1C (P  0.001). The
signiﬁcant associations were still present
after adjusting for the respective values
obtained during blinded CGM use before
randomization.
Factors associated with a reduction
in A1C
Inamultivariatemodelthatincludedsub-
jects with a baseline A1C level 7.0%,
improvement in A1C from baseline to 6
months was associated with higher base-
line A1C level (P  0.001) and greater
CGM use over the 6 months of the study
(P0.001)(Table3).TheSpearmancor-
relation between change in A1C from
baseline to 6 months and average CGM
use over the 6 months of the study was
0.46(supplementaryFig.1,availablein
an online appendix). None of the psycho-
socialmeasureswerepredictiveofchange
in A1C. Age-group was associated with
the change in A1C in a multivariate anal-
ysis including baseline factors (P 
0.004) but after adjustment for the
amount of CGM use, the association was
no longer signiﬁcant (P  0.70). The
main reason was that in all three age-
groups, greater CGM use was associated
withasimilarreductioninA1C.Ascanbe
seen in Fig. 1, in each age-group, subjects
averagingatleast6days/weekofCGMuse
had substantially greater improvement in
A1C than those who used CGM less often
(P0.02inthe25yearage-group,P
0.002 in the 15–24 year age-group, and
P  0.001 in the 8–14 year age-group).
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n overall
(age-groups*)
% 6
days/week in
month 6 overall
(age-groups*) P†
Model 1‡ Model 2§†
OR (95% CI) P OR (95% CI) P
Total 232 53
Age (years) 0.001/NA 0.001 0.001
8–15 74 46 1.00 1.00
15–25 72 29 0.60 (0.28, 1.26) 0.60 (0.29, 1.26)
25 86 79 5.35 (2.48, 11.53) 5.90 (2.78, 12.52)
Sex 0.32/0.39
Female 123 (37, 38, 48) 56 (57, 29, 77)
Male 109 (37, 34, 38) 50 (35, 29, 82)
Race/ethnicity 0.02/0.37
Nonwhite 19 (7, 12, 0) 26 (43, 33, 67)
White, Non-Hispanic 213 (67, 60, 86) 55 (46, 32, 79)
Duration of diabetes (years) 0.001/0.87
5 48 (30, 15, 3) 42 (43, 33, 67)
5–10 70 (35, 27, 8) 47 (49, 30, 100)
10–20 61 (9, 30, 22) 44 (44, 27, 68)
20 53 (0, 0, 53) 81 (0, 0, 81)
Baseline insulin modality 0.006/0.06
Multiple daily injection 42 (10, 22, 10) 33 (30, 23, 60) 1.00 0.45
Pump 190 (64, 50, 76) 57 (48, 32, 82) 1.20 (0.51, 2.84)
Baseline A1C (%) 0.002/0.10 0.28
8.0 63 (27, 26, 10) 38 (44, 23, 60) 1.00
7.0–8.0 102 (29, 31, 42) 53 (45, 23, 81) 1.23 (0.57, 2.65)
7.0 67 (18, 15, 34) 67 (50, 53, 82) 1.69 (0.72, 4.01)
Severe hypoglycemia in last
6 months 0.39/0.64
None 211 (71, 65, 75) 52 (48, 28, 77)
1 episode 21 (3, 7, 11) 62 (0, 43, 91)
Self-reported home
blood glucose
meter measurements
per day¶ 0.001/0.002 0.005 0.002
3–5 68 (16, 31, 21) 28 (13, 16, 57) 1.00 1.00
6–8 104 (34, 26, 44) 61 (53, 27, 86) 3.64 (1.69, 7.84) 4.00 (1.89, 8.47)
9 31 (12, 4, 15) 68 (50, 50, 87) 4.16 (1.45, 11.96) 4.82 (1.72, 13.55)
Education level# 0.04/0.40
12 26 (2, 22, 2) 19 (50, 14, 50)
Associate 23 (8, 6, 9) 57 (38, 50, 78)
Bachelor 90 (32, 21, 37) 61 (53, 38, 81)
Master 65 (21, 14, 30) 55 (38, 36, 77)
Professional 28 (11, 9, 8) 50 (45, 22, 88)
Household income** 0.04/0.26
$25,000 16 (2, 12, 2) 25 (50, 17, 50)
$25,001–$50,000 27 (3, 13, 11) 48 (67, 46, 45)
$50,001–$100,000 74 (24, 14, 36) 65 (58, 43, 78)
$100,000 95 (37, 24, 34) 53 (35, 25, 91)
*Age-groups are 8–14, 15–24, and 25 years. †P values are unadjusted/adjusted for age-group. ‡The multivariate logistic regression model includes all variables
havingage-adjustedP0.20.§MultivariatelogisticregressionmodelusingbackwardselectionkeepingthosevariableswithP0.05.Pvalueobtainedbytreating
as continuous variable. Education level and income category analyzed as ordinal variables. ¶Collected on randomization form, as assessed by clinic personnel over
the last 7 days. Question was added to the case report form after study initialization, and data were missing for 29 subjects in the real-time CGM group. #Education
levelisforparent/guardianforsubjects15yearsoldandforsubjectsaged25years.Forsubjectsinthe15–24yearage-group,educationlevelisthatofthesubject
for 28, of the subject’s spouse for 1, and of the subject’s parent for 43. **Twenty subjects did not provide household income data. In the 15–24 year age-group,
household income reﬂects that of the subject for 35 and that of the parent for 37. NA, not applicable.
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JDRF CGM randomized clinical trial was
to have subjects use a CGM device every
day and incorporate the real-time glucose
informationintotheirdailydiabetesman-
agement to reduce the frequency of high
and low glucose values. Before entering
the study, the subjects were being inten-
sivelytreatedwitheitheraninsulinpump
or multiple daily insulin injections and
were performing frequent blood glucose
monitoring (mean 6.6 measurements/
day). We deﬁned successful use of CGM
asanaverageof6days/weektoallowfor
the possibility of issues such as device in-
operability, exhausted sensor supply, or
other problems that might prevent daily
use for a few days.
As reported previously, among sub-
jects with baseline A1C 7.0%, nearly
daily use after 6 months was strongly as-
sociated with age, with 83% of subjects
25 years sustaining CGM use 6 days/
week compared with 30% of subjects
15–24 years and 50% of subjects 8–14
years (8). After adjustment for age, the
only other baseline factor associated with
successful use after 6 months was the fre-
quency of self-reported prestudy daily
blood glucose meter measurements. Sub-
jectsinallage-groupswhoperformed6
meter measurements/day were more
likely to use CGM on a near-daily basis
than those who were monitoring fewer
times a day. One possible explanation
is that those subjects who were monitor-
ing their blood glucose frequently were
using these multiple glucose measure-
mentstoself-managetheirdiabetesandas
a result could more readily incorporate
information from CGM into their already
intensive diabetes management. In addi-
tion, more frequent home blood glucose
monitoring may be a marker for patients
who are more engaged in their diabetes
self-management and who are therefore
more likely to adhere to a daily CGM reg-
imen as used in this trial.
Notably, none of our surveys, which
were geared to assess baseline psychoso-
cialvariablessuchasfearofhypoglycemia
and perceived diabetes-associated bur-
den,werepredictiveofCGMuse,suggest-
ing that additional research is needed to
identify salient patient beliefs and expec-
tations regarding CGM use. We did not
formally evaluate subject expectations for
CGM at study entry, and such an assess-
mentmightprovetobeapredictorofsus-
tained long-term use.
CGM use in the 1st month was very
high, with 90% of subjects using CGM
on at least 21 of the ﬁrst 28 days. Subjects
whousedtheCGMdeviceatleast27of28
days in the 1st month were more likely to
sustain near-daily use through month 6
than those who used CGM less often.
However, because of the overall high de-
gree of use, the study had limited ability
to evaluate whether CGM use in the 1st
month could be used to predict the like-
lihood of long-term CGM use. This high
degreeofearlyusecouldreﬂectinpartthe
fact that successful use of a blinded CGM
device during a prerandomization run-in
period was required for study entry.
A higher percentage of CGM glucose
values in the range of 71 to 180 mg/dl
during the 1st month (with fewer values
180 mg/dl) were predictive of greater
use in month 6 even after adjustment for
the amount of CGM use. This could re-
Table 2—CGM use and sensor glucose values during 1st month as predictors of
month 6 CGM use
n*
Sensor use 6
days/week
during month 6
Odds ratio
(95% CI) P†
Sensor use during ﬁrst 7 days 0.14
0–5‡ 8 2 (25) 1.00
6 19 7 (37) 1.70 (0.23–12.63)
7 204 114 (56) 3.13 (0.55–17.71)
Sensor use during ﬁrst 14 days 0.03
4–8 13 4 (31) 1.00
9–11 14 4 (29) 2.22 (0.34–14.53)
12–13 26 11 (42) 2.83 (0.56–14.26)
14 178 104 (58) 4.26 (1.08–16.84)
Sensor use during ﬁrst 21 days 0.001
7–13 14 3 (21) 1.00
14–17 13 6 (46) 9.93 (1.48–66.83)
18–20 53 18 (34) 3.35 (0.70–16.05)
21 151 96 (64) 8.86 (2.03–38.63)
Sensor use during ﬁrst 28 days 0.001
7–20 20 4 (20) 1.00
21–23 19 7 (37) 4.52 (0.90–22.63)
24–26 34 10 (29) 2.43 (0.55–10.72)
27–28 158 102 (65) 7.19 (2.04–25.37)
Sensor use during 15–28 days
0–10 28 7 (25) 1.00 0.001
11–13 57 19 (33) 1.57 (0.50–4.89)
14 146 97 (66) 4.80 (1.72–13.37)
% of day 71–180 mg/dl during
1st month§ 0.002
20–55 64 13 (20) 1.00
55–70 94 56 (60) 3.39 (1.50–7.66)
70–95 73 54 (74) 3.82 (1.52–9.57)
%o fd a y70 mg/dl during
1st month§ 0.91
5–31 77 38 (49) 1.00
2–5 77 43 (56) 1.71 (0.79–3.74)
0–2 77 42 (55) 1.43 (0.64–3.19)
%o fd a y180 mg/dl during
1st month§ 0.006
40–79 68 18 (26) 1.00
25–40 86 50 (58) 2.09 (0.95–4.63)
1–25 77 55 (71) 2.42 (1.01–5.85)
Data are n (%) or OR (95% CI). *n  231. One subject is missing sensor data for the 1st month because of
a defective device that could not be downloaded. †P values are from logistic regression model treating CGM
use as a continuous variable, adjusting for age and baseline number of blood glucose meter measurements/
day. Categories were created for presentation purposes. ‡One subject had zero use, 1 subject had 1 day of
use, 4 subjects had 4 days of use, and 2 subjects had 5 days of use. §Logistic regression models adjusted for
age, baseline number of blood glucose meter measurements/day, and sensor use during the 1st month.
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most beneﬁt early in their usage of CGM
were more likely to recognize the advan-
tages of sustained use of CGM. Con-
versely, individuals with more values
180 mg/dl may have felt discouraged
and therefore less inclined to use the de-
vice. Alternatively, frequent sensor values
180 mg/dl may be a marker for persons
less attentive or too busy to attend to di-
abetesmanagementandtheadditionalef-
fort that CGM usage entails. Ongoing
education and support may assist these
patients in achieving equivalent CGM
beneﬁt.
We also analyzed the beneﬁt of CGM
as measured by A1C in those whose base-
line A1C was 7.0%. The amount of
CGM use was strongly associated with
change in A1C, similar to what was seen
in other trials (15). In all three age-
groups, near-daily use of CGM was asso-
ciatedwithsimilarimprovementsinA1C.
In fact, the association between age and
CGM use accounted for the association
between age and change in A1C. Higher
baseline A1C was associated with a
greater A1C drop from baseline to 6
months but not greater CGM use. This
probablyisrelatedtoaﬂooreffectinthose
who started with lower A1C levels. Less
time with glucose values 180 mg/dl
during the 1st month was associated with
greater CGM use in month 6.
Our results need to be interpreted
within the context of the enrollment cri-
teria for the study, which required inten-
sivediabetesmanagementwithaninsulin
pump or multiple daily injections, fre-
quent home blood glucose monitoring,
and successful completion of a run-in pe-
riod of blinded CGM use. For such pa-
tients, our results have shown that long-
term consistent CGM use is more
frequent in adults than in children or ad-
olescents, but a similar beneﬁt on A1C is
seen in patients of all ages who regularly
useCGM.CGMuseinthe1stmonthmay
help predict the likelihood of long-term
beneﬁt, and our results suggest that a trial
of CGM use for several weeks may help
predict long-term use and consequent
beneﬁt.BecauseregularuseofCGMisnot
observedinallpatientswithtype1diabe-
tes,particularlychildrenandadolescents,
further research is needed to better un-
derstand and overcome the barriers to
daily CGM use.
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Table 3—Baseline factors predictive of change in A1C from baseline to 6 months in subjects
with baseline A1C >7.0%
n Mean*
P
Univariate
models Model 1† Model 2‡
Total 162 0.35
Sex 0.55
Female 86 0.32
Male 76 0.38
Age-group 0.08 0.004 0.70
8–15 years 56 0.37
15–25 years 56 0.18
25 years 50 0.50
Race/ethnicity 0.69
White, Non-Hispanic 148 0.35
Nonwhite 14 0.27
Baseline insulin modality 0.51
Multiple daily injection 35 0.27
Pump 127 0.37
Baseline A1C§ 0.001 0.001 0.001
7.0–7.5% 47 0.11
7.5–8.0% 53 0.36
8.0% 62 0.52
Severe hypoglycemia in last 6 months 0.76
None 149 0.34
1 episode 13 0.41
Self-reported home blood glucose per
day§ 0.27
3–5 55 0.16
6–8 69 0.36
91 5 0.34
Education level of primary
caregiver§¶ 0.78
12 20 0.38
Associate 19 0.21
Bachelor 58 0.43
Master 45 0.32
Professional 20 0.26
Household income§# 0.89
$25,000 13 0.25
$25,001–$50,000 17 0.47
$50,001–$100,000 49 0.39
$100,000 67 0.33
No. days per week of sensor use
during 6 months 0.001 0.001
4 days 18 0.02
4–6 days 56 0.10
6 days 88 0.58
*Negative change denotes improvement and positive change is worsening. †Includes all baseline variables
with univariate P 0.20 (does not include sensor use). ‡Includes all variables in model 1 plus CGM use. §P
valueobtainedbytreatingasacontinuousvariable.Educationlevelandincomecategoryanalyzedasordinal
variables. Collected on randomization form, as assessed by clinic personnel over the last 7 days. Question
was added to the case report form after study initialization and data were missing for 29 subjects in the
real-time CGM group. ¶Education level is for parent/guardian for subjects 15 years old and for subjects
aged 25 years. For subjects in the 15–24 age-group, education level is that of the subject for 28, of the
subject’sspousefor1,andofthesubject’sparentfor43.#20subjectsdidnotprovidehouseholdincomedata.
Inthe15–24yearage-group,householdincomereﬂectsthatofthesubjectin35andthatoftheparentin37.
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